Stock ANL ADLAI NORTYE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Adlai Nortye Ltd.

Equities

ANL

US00704R1095

Delayed Nasdaq
Other stock markets
 10:23:11 2024-06-28 EDT 		5-day change 1st Jan Change
3.26 USD -12.12% Intraday chart for Adlai Nortye Ltd. -10.68% -63.74%
05-24 Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024 CI
05-22 Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024
Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Adlai Nortye Announces Appointment of Archie Tse as the Head of Research & Development
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
Adlai Nortye Ltd. has completed an IPO in the amount of $57.5 million.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANL Stock
  4. News Adlai Nortye Ltd.
  5. Other languages